Veröffentlichungen

Highlights vom Kongress ASCO 2022 zur Therapie mit CDK4/6-Inhibitoren

Statement Dr. med. Thomas Göhler zur PALOMA-2-Studie: Postmenopausale Frauen mit HR+ / HER2- metastaiertem Brustkrebs ohne Vorbehandlung

  • First interim results from a non-interventional study in hepatocellular carcinoma patients treated with sorafenib – the INSIGHT study

    • Autoren: PD Dr. T.M. Ganten, Department of Internal Medicine, University of Heidelberg, Germany
    • Co-Authoren:  E. Schott, T. Göhler, R. Wiest, P. Malfertheiner, R. Stauber, R. Buder, K. Achilles, G. Gerken
    • DGHO 2011

  • Erste Zwischenergebnisse der prospektiven, nicht-interventionellen INSIGHT-Studie mit Sorafenib bei Patienten mit hepatozellulärem Karzinom

    • Autoren: Ganten TM 1, Schott E 2, Göhler T 3, et al.
    • DGVS März 2011

  • 24 month follow-up from the Patient’s Anastrozole Compliance to Therapy Programme (PACT) evaluation the influence of a stanardized information serviec on compliance in postmenopausal women with early breast cancer

    • Autoren: Prof. Lück, Prof. Hadji, Prof. Harbeck, Prof. Jakisch, Prof. Blettner, Dr. Göhler et al.
    • ASCO 2011

  • A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: Results of the PELICAN study

    • Autoren: Nadia Harbeck, Steffen Saupe, Elke Jäger, Markus Schmidt, Rolf Kreienberg, Lothar Müller, Burkhard Joerg Otremba, Dirk Waldenmaier, Julia Dorn, Mathias Warm, Michael Scholz, Michael Untch, Maike de Wit, Andreas du Bois, Hans-Joachim Lück, Philipp Harter, Thomas Göhler, Doris Augustin, Paul Harnett, Rainer Lipp, Matthias Beckmann, Salah-Eddin Al-Batran, on behalf of the PELICAN investigators.
    • ASCO 2010

  • A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer

    • Autoren: Jens Hiober, Breast Center Kantonspital St. Gallen, Switzerland; Werner Fett, Oncological Practice Wuppertal, Germany; Arnd Nusch, Oncological Practice Velbert, Germany; Michael Neise, Oncological Practice Krefeld, Germany; Marcus Schmidt, University of Mainz Dept. Of Gynecology Mainz, Germany; Arthr wischnik, Clinical Center Augsburg, Germany; Steffen Gerhardt, Oncological Practice Gera, Germany; Thomas Goehler, Oncological Practice Dresden, Germany; Hans-Joachim Lück, Hannover Medical School, Germany; Andreas Rost, Clinical Center Darmstadt, Germany
    • BioMed Central – BMC Cancer Januar 2010

  • Therapie der Eisenintoxikation – 22 Exjade – Fallberichte aus der Praxis

    • Autoren: Gritta Janka-Schaub, Detlef Haase
      unter Mitarbeit von Y. Dencausse, S. Dörfel, A. Eisfeld. S.E lezkurtaj, F. Fox, K. Götze, R.Grosse, M. Haak, W-K. Hofmann, A. Jarisch, M. Just, U. Kordes, V. Lackner, A. Mohr, J. Radke, A. Röht, J. Schanz, C. Scheid, T. Seiler, K. Zirlik
    • Thieme Verlag 2009

  • A Multicentric Observational Trial of Pegylated Liposomal Doxorubicin for Metastatic Breast Cancer

    • Autoren: Huober Jens, Breast Center Kantonsspital, St. Gallen, Switzerland; Fett Werner, Oncological Practice, Wuppertal, Germany; Nusch Arnd, Oncological Practice, Velbert, Germany; Neise Michael, Oncological Practice, Krefeld, Germany; Schmidt Marcus, University of Mainz, Dept of Gynecology, Mainz, Germany; Wischnik Arthur, Clinical Center Augsburg, Augsburg, Germany; Gerhard Steffen, Oncological Practice, Gera, Germany; Goehler Thomas, Oncological Practice, Dresden, Germany; Rost Andreas , Clinical Center Darmstadt, Darmstadt, Germany
    • Target Journal Oncology 2009

  • Treatment of patients with advanced or metastatic Renal Cell Carcinoma (RCC-Registry): A „REAL LIFE“ treatment overview of non-trial patients in outpatient cancer centres in Germany

    • Autoren: Müller, L., Münch, A., Blumenstengel, K., Sauer, U., Goebell, P.J., Hipper, A.
    • DGHO 2009

  • Auswirkungen eines standardisierten Informationsprogrammes auf die Complaince in der endokrinen Therapie postmenopausaler Frauen mit frühem Mammakarzinom: Erste Daten aus dem Patient’s Anastrozole Compliance to Therapy Programme (PACT)

    • Autoren: Lück HJ., Harbeck N., Blettner M., Hadji P., Jackisch C., Schmitt DC., Haidinger R., Rexrodt von Fircks A., Schulte H., Martin RR., Jäger D., Zaun S., Kreienberg R., Gemeinschaftspraxis Göhler/Dörfel
    • Deutsche Gesellschaft für Senologie 2009
    • Georg Thieme Verlag Stuttgart – New York
    • ISSN 1611 – 6453

  • Results of a prospective observational study on the efficacy and safety of Pegfilgrastim administered to cancer patients treated with chemotherapy

    • Autoren: Lange O.F., Stickeler E., Doerfel S., Goehler T., Polnau D., Tauer R., Soelch J-P.
    • Onkologie – International Journal for Cancer Research and Treatment, Oktober 2008

  • Routine clinical Use of Trastuzumab for advanced / metastatic breast cancer in Germany and its utility in continued treatment beyond disease progression – a prospective observational study

    • Autoren: C. Jackisch, H. Eustermann, W. Schoenegg, U. Söling, M. Stauch, T. Goehler, W. Kuehn, W.Krieger, D.Reichert
    • „Annals of Oncology“, 2008

  • Docetaxel – Cisplatin (DC) vs. 5 – FU – Leucovorin – Cisplatin (FLC) as first-line treatment for locally advanced or metastatic gastric cancer: Preliminary results of a phase III study

    • Autoren: Ridwelski K., Göhler, T. et al.
    • American Society of Clinical Oncology, 2008

Weiterlesen